### Communications to the editor


# 6β-HALOPENICILLANIC ACIDS, A GROUP OF β-LACTAMASE INHIBITORS

Sir:

Recent reports have described the preparation of a novel  $\beta$ -lactamase inhibitor,  $6\beta$ -bromopenicillanic acid  $(1a)^{1-41}$ , obtained as a mixture with its inactive  $6\alpha$ -bromo epimer  $2a^{51}$ , either by aqueous equilibration of the latter at pH 9.1 and 30°C for  $3 \sim 4$  days or by selective reduction of 6,6-dibromopenicillanic acid  $(3)^{61}$ . However, the isolation of pure 1a from such mixtures has not been previously recorded. The present communication describes the isolation of  $6\beta$ -bromopenicillanic acid (1a) as well as the analogous  $6\beta$ -chloro and  $6\beta$ -iodo compounds 4a and 5a by separation of mixtures with the corresponding  $6\alpha$ -halopenicillanic acids from which they were prepared\*.

Incubation of 0.1 M aqueous potassium  $6\alpha$ bromopenicillanate (2b) (300 ml) at pH 9.0 (pHstat) and 30°C for 24 hours provided a mixture of 1b and 2b in an approximate ratio of 25:75 as shown by <sup>1</sup>H-NMR spectroscopy. After addition of diethyl ether (200 ml) and acidification (pH 3) of the stirred mixture at 5°C with 4 N hydrochloric acid, the resulting organic extract was dried and concentrated at reduced pressure to about 40 ml. The concentrate was subjected to dry-column chromatography on silica gel (Silica Woelm TSC, 600 g), the column (quartz glass,  $6 \times 50$  cm) being treated with 100 ml of developing solvent (diethyl ether - petroleum ether - formic acid, 70: 30: 0.1) before loading. Separation of the epimeric mixture was accomplished with 1,200 ml of developing solvent, the major part of the  $6\alpha$ -bromo epimer 2a being eluted into the outflow. From the bottom of the column, segments (2 cm each) were scraped out, suspended in ethyl acetate (10 ml), and

\* Subsequent to the completion of this work a report describing the preparation of pure sodium  $6\beta$ -bromopenicillanate through stereoselective reduction of trimethylsilyl 6,6-dibromopenicillanate with tri-*n*-butyltin hydride followed by hydrolysis and sodium salt formation has appeared.<sup>7)</sup>



aliquots (5  $\mu$ l) of the supernatants were examined by thin-layer chromatography (Silica Gel 60 F-254, Merck) using the above developing solvent (2 runs). Fractions containing the pure  $6\beta$ bromo epimer 1a were combined and eluted with ethyl acetate. The resulting extract was concentrated *in vacuo* to about 40 ml, washed thoroughly with water to remove formic acid, and dried. Further evaporation of the concentrate to about 5 ml afforded precipitation of crystalline  $6\beta$ -bromopenicillanic acid (1a) which, after recrystallization from diethyl ether, decomposed at 80~100°C without melting;  $[\alpha]_D^{20} + 272^\circ$  (*c* 0.5, CHCl<sub>3</sub>).

Similarly, equilibration (pH 9.0~9.2, 30°C,

Table 1. <sup>1</sup>H-NMR spectra of  $\beta\beta$ -halopenicillanic acids in CD<sub>3</sub>CN. Signals listed in  $\delta$  values using TMS as internal reference.

Position of protons	Chemical shift $(\delta)$		
	1a	4a	5a
$2\alpha$ -CH <sub>3</sub>	1.51 s	1.51 s	1.49 s
$2\beta$ -CH <sub>3</sub>	1.63 s	1.61 s	1.65 s
3-H	4.46 s	4.45 s	4.45 s
5-H	5.48 d J=4.0	5.38 d J=4.0	5.35 d J=4.0
6-H	5.54 d J=4.0	5.58 d J=4.0	5.74 d J=4.0

s=singlet, d=doublet, J=coupling constant in Hz.

24 hours) of 0.1 M aqueous solutions of potassium  $6\alpha$ -chloropenicillanate (6b)<sup>5</sup> and the corresponding  $6\alpha$ -iodo derivative 7b (obtained after hydrolysis and salt formation from the acetoxymethyl ester 8 prepared in analogy to a published method<sup>8)</sup>) provided epimeric mixtures containing  $10 \sim 15$  and  $30 \sim 35\%$ , respectively, of the  $6\beta$ halopenicillanates 4b and 5b as indicated by <sup>1</sup>H-NMR spectroscopy. After extraction of the acidified mixtures (pH 3) with diethyl ether, the  $6\beta$ -halo acids (4a, 5a) were separated from the respective 6-epimers (6a, 7a) by dry-column chromatography on silica gel using the same procedure as described above. On concentration of the eluates, the pure  $6\beta$ -epimers crystallized from ethyl acetate to afford, after recrystallization from diethyl ether-diisopropyl ether, 4a,  $[\alpha]_{\rm p}^{20} + 264^{\circ}$  (c 0.5, CHCl<sub>3</sub>); and 5a,  $[\alpha]_{\rm p}^{20} + 276^{\circ}$ (c 0.5, CHCl<sub>3</sub>). Both compounds decomposed at  $80 \sim 100^{\circ}$ C without melting.

As apparent from the <sup>1</sup>H-NMR data (Table 1), the  $\beta$ -lactam protons in **1a**, **4a**, and **5a** have a larger coupling constant (J=4.0 Hz) than that observed in  $6\alpha$ -halopenicillanates (J=1.5 Hz)<sup>6,9,10</sup>, and therefore the  $6\beta$ -halo compounds contain a *cis*-oriented  $\beta$ -lactam and have the 5*R*, 6*R*configuration.

Alternatively, the 6 $\beta$ -halo acids could be isolated, after salt formation with 1 M aqueous potassium bicarbonate and removal of water by azeotropic distillation with *n*-butanol, as the crystalline potassium salts **1b**,  $[\alpha]_{D}^{20}+253^{\circ}$  (*c* 0.5, 1 M phosphate buffer pH 7); **4b**,  $[\alpha]_{D}^{20}+243^{\circ}$  (*c* 0.5, 1 M phosphate buffer pH 7); and **5b**,  $[\alpha]_{D}^{20}$  $+260^{\circ}$  (*c* 0.5, 1 M phosphate buffer pH 7).

The 6 $\beta$ -halopenicillanic acids were further characterized as the corresponding pivaloyloxymethyl esters 9, m.p. 67~68°C,  $[\alpha]_{\rm D}^{20}+197^{\circ}$ (c 0.5, CHCl<sub>3</sub>); 10, m.p. 68~69°C,  $[\alpha]_{\rm D}^{20}+185^{\circ}$ (c 0.5, CHCl<sub>3</sub>); and 11, m.p. 78~79°C,  $[\alpha]_{\rm D}^{20}$ +201° (c 0.5, CHCl<sub>3</sub>), obtained from the potassium salts 1b, 4b, and 5b on treatment with chloromethyl pivalate in dimethylformamide.

The  $6\beta$ -halopenicillanic acids exhibit only weak antibacterial activity against most Grampositive and Gram-negative bacteria (with the exception of the genus *Neisseria*), but are potent inhibitors, in particular **1a** and **5a**, of various types of  $\beta$ -lactamases. Thus, the inhibitory activities of  $6\beta$ -bromopenicillanic acid (**1a**) and its iodo analog **5a**, *e.g.* against the enzymes from *Staphylococcus aureus* and *Escherichia coli* (RT- EM), compare favorably with that of clavulanic acid, whereas  $6\beta$ -chloropenicillanic acid (4a) is less active\*.

## Acknowledgements

The author is indebted to HANNE GREEN and ANNETTE NIELSEN for excellent technical assistance, and to Dr. N. RASTRUP-ANDERSEN for the spectral data.

#### Welf von Daehne

Leo Pharmaceutical Products DK-2750 Ballerup, Denmark

(Received January 21, 1980)

#### References

- LOOSEMORE, M. J. & R. F. PRATT: On the epimerization of 6α-bromopenicillanic acid and the preparation of 6β-bromopenicillanic acid. J. Org. Chem. 43: 3611~3613, 1978
- PRATT, R. F. & M. J. LOOSEMORE: 6β-Bromopenicillanic acid, a potent β-lactamase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 75: 4145~4149, 1978
- KNOTT-HUNZIKER, V.; B. S. ORLEK, P. G. SAMMES & S. G. WALEY: 6β-Bromopenicillanic acid inactivates β-lactamase I. Biochem. J. 177: 365~367, 1979
- KNOTT-HUNZIKER, V.; S. G. WALEY, B. S. ORLEK & P. B. SAMMES: Penicillinase active sites: Labelling of serine-44 in β-lactamase I by 6β-bromopenicillanic acid. FEBS Letters 99: 59~61, 1979
- CIGNARELLA, G.; G. PIFERRI & A. TESTA: 6-Chloro- and 6-bromopenicillanic acids. J. Org. Chem. 27: 2668~2669, 1962
- CLAYTON, J. P.: The chemistry of penicillanic acids. I. 6,6-Dibromo- and 6,6-diiodo-derivatives. J. Chem. Soc. (C) 1969: 2123~2127, 1969
- AIMETTI, J. A.; E. S. HAMANAKA, D. A. JOHNSON & M. S. KELLOGG: Stereoselective synthesis of 6β-substituted penicillanates. Tetrahedron Lett. 1979: 4631~4634, 1979
- DININNO, F.; T. R. BEATTIE & B. G. CHRISTEN-SEN: Aldol condensations of regiospecific penicillanate and cephalosporanate enolates. Hydroxyethylation at C-6 and C-7. J. Org. Chem. 42: 2960~2965, 1977
- MCMILLAN, I. & R. J. STOODLEY: A novel rearrangement of methyl 6-chloropenicillanate. Tetrahedron Lett. 1966: 1205~1210, 1966
- CLAYTON, J. P.; J. H. C. NAYLER, R. SOUTHGATE & E. R. STOVE: Penicillanic acids: Requirements for epimerisation at C-6. J.C.S., Chem. Comm. 1969: 129~130, 1969

<sup>\*</sup> Personal communication from Dr. BODIL BALTZER.